By Colin Kellaher

 

Novartis AG on Thursday said the U.S. Food and Drug Administration granted fast-track designation to LNA043 for the treatment for osteoarthritis of the knee.

The Swiss drug maker said it is developing LNA043 as a potential first-in-class disease-modifying treatment for osteoarthritis.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Novartis said it currently is conducting a Phase IIb study in patients with the chronic degenerative disease that is characterized by a progressive loss of cartilage, leading to pain, loss of joint function and disability.

Novartis said treatment with intra-articular injections of LNA043 in a proof-of-concept study resulted in regeneration of damaged cartilage in patients with femoral articular cartilage lesions.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 02, 2021 06:42 ET (10:42 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Novartis.